The prospective study of blood biomarker and gut microbiota in the patients treated with anti-PD 1 antibody for advanced non-small cell lung cancer

Trial Profile

The prospective study of blood biomarker and gut microbiota in the patients treated with anti-PD 1 antibody for advanced non-small cell lung cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 26 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 14 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top